We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$3.07B
AUM Growth
+$88.4M
Cap. Flow
+$123M
Cap. Flow %
3.99%
Top 10 Hldgs %
53.1%
Holding
48
New
8
Increased
13
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$186M
2
MDT icon
Medtronic
MDT
+$151M
3
CELG
Celgene Corp
CELG
+$133M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$132M
5
BAX icon
Baxter International
BAX
+$111M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$180M
2
DHR icon
Danaher
DHR
+$103M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$78.6M
4
LH icon
Labcorp
LH
+$72.6M
5
JNJ icon
Johnson & Johnson
JNJ
+$68M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$321B
$219M 7.14%
4,087,200
+3,362,739
+464% +$186M
BIVV
2
DELISTED
Bioverativ Inc. Common Stock
BIVV
$202M 6.58%
3,750,000
-400,000
-10% -$21.9M
ZBH icon
3
Zimmer Biomet
ZBH
$18.4B
$184M 5.99%
1,570,750
-172,844
-10% -$19.5M
CELG
4
DELISTED
Celgene Corp
CELG
$180M 5.86%
1,725,000
+1,181,820
+218% +$133M
LH icon
5
Labcorp
LH
$25.9B
$175M 5.71%
1,280,400
-549,746
-30% -$72.6M
MDT icon
6
Medtronic
MDT
$110B
$157M 5.12%
1,950,000
+1,883,900
+2,850% +$151M
AGN
7
DELISTED
Allergan plc
AGN
$135M 4.39%
825,000
+251,790
+44% +$45.2M
INCY icon
8
Incyte
INCY
$24.9B
$128M 4.16%
1,350,000
+751,450
+126% +$78.5M
PCRX icon
9
Pacira BioSciences
PCRX
$1.06B
$128M 4.16%
2,800,000
+221,960
+9% +$8.8M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$77.4B
$122M 3.98%
+325,000
New +$132M
NBIX icon
11
Neurocrine Biosciences
NBIX
$18.7B
$118M 3.85%
1,525,000
-562,110
-27% -$38.3M
BAX icon
12
Baxter International
BAX
$13.8B
$112M 3.63%
+1,725,000
New +$111M
VRTX icon
13
Vertex Pharmaceuticals
VRTX
$122B
$109M 3.54%
725,000
+690,050
+1,974% +$102M
HAE icon
14
Haemonetics
HAE
$3.85B
$84.2M 2.74%
1,450,000
-2,343
-0.2% -$123K
CVS icon
15
CVS Health
CVS
$134B
$81.6M 2.65%
+1,125,000
New +$81.8M
ISRG icon
16
Intuitive Surgical
ISRG
$126B
$80.8M 2.63%
664,410
+439,050
+195% +$54.9M
IQV icon
17
IQVIA
IQV
$39.1B
$76.7M 2.5%
+783,380
New +$79.7M
SRPT icon
18
Sarepta Therapeutics
SRPT
$1.64B
$72.9M 2.37%
1,309,960
+107,190
+9% +$5.68M
ABBV icon
19
AbbVie
ABBV
$455B
$72.5M 2.36%
749,410
-236,910
-24% -$22.3M
ELV icon
20
Elevance Health
ELV
$81.6B
$71.1M 2.32%
+316,180
New +$67.3M
UNH icon
21
UnitedHealth
UNH
$383B
$69.4M 2.26%
315,000
-67,990
-18% -$14.4M
MD icon
22
Pediatrix Medical
MD
$2.17B
$67.4M 2.19%
+1,261,620
New +$59.5M
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
$66.2M 2.16%
973,840
+326,420
+50% +$22.8M
HUM icon
24
Humana
HUM
$44B
$65.4M 2.13%
263,440
+2,570
+1% +$635K
LIVN icon
25
LivaNova
LIVN
$4.45B
$49.8M 1.62%
622,997
-308,533
-33% -$24.5M
1
2

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q4 2017 Portfolio in Review

As of Q4 2017, HealthCor Management held 48 positions worth $3.07B, up 3% from $2.98B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

HealthCor Management deployed $123M of net new capital in Q4 2017, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 325,000 shares worth $122M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 78% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Danaher, an estimated $103M trimmed.

  • HealthCor Management's largest Q4 2017 buy was Regeneron Pharmaceuticals: 325,000 shares worth $122M.
  • HealthCor Management added most to Merck in Q4 2017, an estimated $186M increase.
  • HealthCor Management's biggest Q4 2017 reduction was Danaher, cutting an estimated $103M.
  • HealthCor Management fully exited Aetna Inc in Q4 2017, selling an estimated $180M.
  • HealthCor Management's ten largest holdings make up 53% of its $3.07B portfolio in Q4 2017.
  • HealthCor Management opened 8 new positions and closed 11 in Q4 2017.
  • HealthCor Management's portfolio value rose 3% quarter-over-quarter to $3.07B.

Based on HealthCor Management's 13F filing for Q4 2017, filed 14 Feb 2018.